基本資料

投資策略

此成分基金的目標是藉投資於由在醫療行業作為創新先鋒的生物醫藥公司所發行的股票或類似證券，以達致增長。成分基金將至少以其淨資產的三分之二投資於由從事該行業的公司所發行的股票。此成分基金的投資並沒有地域上的限制，但由於醫藥行業所有創新產品集中於北美及西歐，此成分基金的大部分投資亦集中於這些地區。為了就醫藥行業的創新項目提供資金，此生物科技成分基金最多可以其淨資產的10%投資於私人股票及／或非上市證券。

基金經理人

• Martin-Fougeroux Eugénio
• 資歷 2年(2023-01-01 至今)

• Minonne Marco
• 資歷 5年(2020-06-01 至今)

• Marco Minonne, CFA, Senior Vice President, rejoined the firm in 2013. Marco is part of the Growth Equity Group which is responsible for Neuberger Berman’s Mid Cap Growth and Small Cap Growth strategies. He is an Associate Portfolio Manager on Small Cap Growth and a Research Analyst covering the health care sector on Mid Cap Growth. Prior to rejoining Neuberger Berman, Marco was a senior therapeutic analyst with Columbia Management. He has previously held research analyst positions at Citadel Investment Group, Neuberger Berman and Northern Trust Bank. Marco has extensive buy-side experience in health care and has been involved in both long-only and long-short strategies. Marco earned a Bachelor of Arts in Finance and Economics from the University of Iowa and has been awarded the Chartered Financial Analyst designation.

• Storni Tazio
• 資歷 9年(2016-05-26 至今)

基金費用

聯絡資訊